MolecularMD Lands $3,000,000 New Funding Round
2611 SW 3rd Ave. Portland, OR 97201
Founded in 2006, MolecularMD is a molecular diagnostics company specializing in clinical development and commercialization of state-of-the-art genomic assays to measure patient response and resistance to targeted cancer therapies. The company has over 30 years of combined experience in cancer research and has developed sensitive and highly reliable molecular assays for leukemias, lymphomas, and solid tumors.
This financing will be used to build MolecularMD’s corporate infrastructure and to expand the company’s assay portfolio.
Ballast Point Venture Partners
Trending on Xconomy
[toplytics period="week" numberposts="3"]